Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
Saved in:
Main Authors: | Espada G (Author), Pardeo M (Author), Chaitow J (Author), Brown D (Author), Allen R (Author), Zulian F (Author), Zuber Z (Author), Wulffraat N (Author), Joos R (Author), Dolezalova P (Author), Burgos-Vargas R (Author), Woo P (Author), Schneider R (Author), Ruperto N (Author), Brunner H (Author), De Benedetti F (Author), Flato B (Author), Gerloni V (Author), Horneff G (Author), Wright S (Author), Kenwright A (Author), Lovell D (Author), Martini A (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2011-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
by: De Benedetti Fabrizio, et al.
Published: (2012) -
Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
by: Livermore P, et al.
Published: (2008) -
Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
by: Yamaguchi Ken-ichi, et al.
Published: (2012) -
The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA
by: Grant Schulert, et al.
Published: (2024) -
The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study
by: Fabrizio de Benedetti, et al.
Published: (2024)